Alzheimer's association welcomes UK approval of Leqembi but criticizes NHS access denial
- The UK's MHRA has approved Leqembi (Lecanemab) for treating Alzheimer's disease.
- This marks the first Alzheimer's therapy approved in the UK.
- NICE has decided not to provide access to Leqembi through the NHS, raising concerns about healthcare inequality.
- Leqembi targets Amyloid-beta, a key component of Alzheimer's disease, and has shown significant benefits in clinical trials.
Read more
